Sangamo Therapeutics, Inc. (SGMOQ)
0.1102
-0.03
(-21.79%)
USD |
OTCM |
Oct 16, 16:00
Sangamo Therapeutics Cash from Operations (Quarterly) : -19.28M for March 31, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | -19.28M |
| December 31, 2025 | -24.40M |
| September 30, 2025 | -28.50M |
| June 30, 2025 | -18.16M |
| March 31, 2025 | -26.15M |
| December 31, 2024 | -3.351M |
| September 30, 2024 | 11.76M |
| June 30, 2024 | -26.88M |
| March 31, 2024 | -48.66M |
| December 31, 2023 | -50.54M |
| September 30, 2023 | -47.29M |
| June 30, 2023 | -60.71M |
| March 31, 2023 | -66.30M |
| December 31, 2022 | -57.05M |
| September 30, 2022 | -53.62M |
| June 30, 2022 | -53.98M |
| March 31, 2022 | -58.98M |
| December 31, 2021 | -52.71M |
| September 30, 2021 | -59.42M |
| June 30, 2021 | -52.57M |
| March 31, 2021 | -68.55M |
| December 31, 2020 | -4.295M |
| September 30, 2020 | 33.07M |
| June 30, 2020 | 159.99M |
| March 31, 2020 | -18.89M |
| Date | Value |
|---|---|
| December 31, 2019 | -20.82M |
| September 30, 2019 | -38.87M |
| June 30, 2019 | -39.59M |
| March 31, 2019 | -45.12M |
| December 31, 2018 | -39.56M |
| September 30, 2018 | -27.60M |
| June 30, 2018 | 122.44M |
| March 31, 2018 | -18.13M |
| December 31, 2017 | -16.84M |
| September 30, 2017 | -15.69M |
| June 30, 2017 | 56.79M |
| March 31, 2017 | -13.08M |
| December 31, 2016 | -12.30M |
| September 30, 2016 | -17.04M |
| June 30, 2016 | -16.18M |
| March 31, 2016 | -20.36M |
| December 31, 2015 | -9.104M |
| September 30, 2015 | -14.20M |
| June 30, 2015 | -8.025M |
| March 31, 2015 | -2.393M |
| December 31, 2014 | -2.712M |
| September 30, 2014 | -5.768M |
| June 30, 2014 | -8.574M |
| March 31, 2014 | 11.38M |
| December 31, 2013 | -1.337M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -177.47M |
| Oncolytics Biotech, Inc. | -8.066M |
| Sarepta Therapeutics, Inc. | 197.07M |
| Anixa Biosciences, Inc. | -1.77M |
| Vicapsys Life Sciences, Inc. | -0.0051M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -0.013M |
| Cash from Financing (Quarterly) | 26.70M |
| Free Cash Flow | -90.46M |
| Free Cash Flow Per Share (Quarterly) | -0.0495 |
| Free Cash Flow to Equity (Quarterly) | -11.83M |
| Free Cash Flow to Firm (Quarterly) | -19.30M |
| Free Cash Flow Yield | -254.8% |